HC Wainwright Issues Optimistic Forecast for SLNO Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Stock analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for Soleno Therapeutics in a report issued on Monday, March 31st. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.80) per share for the quarter, up from their prior forecast of ($0.83). HC Wainwright currently has a "Buy" rating and a $100.00 price objective on the stock. The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics' Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.76) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.37 EPS, Q4 2026 earnings at $1.06 EPS and FY2026 earnings at $1.39 EPS.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.41).

SLNO has been the topic of a number of other reports. Cantor Fitzgerald lifted their price objective on Soleno Therapeutics from $67.00 to $123.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. UBS Group set a $105.00 price target on Soleno Therapeutics in a research report on Thursday, March 27th. Robert W. Baird upped their price target on Soleno Therapeutics from $72.00 to $102.00 and gave the stock an "outperform" rating in a report on Thursday, March 27th. Laidlaw raised their price objective on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the stock a "buy" rating in a research note on Thursday, March 27th. Finally, Lifesci Capital upgraded shares of Soleno Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 4th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $99.63.

Remove Ads

Soleno Therapeutics Trading Down 6.3 %

SLNO traded down $4.39 during trading on Thursday, hitting $65.25. The stock had a trading volume of 1,004,381 shares, compared to its average volume of 677,774. The firm has a market cap of $2.99 billion, a PE ratio of -19.62 and a beta of -2.29. Soleno Therapeutics has a 12 month low of $36.61 and a 12 month high of $74.00. The company has a 50 day simple moving average of $51.64 and a 200-day simple moving average of $50.84.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC grew its position in Soleno Therapeutics by 27.1% during the 4th quarter. Janus Henderson Group PLC now owns 5,188,265 shares of the company's stock worth $233,130,000 after acquiring an additional 1,107,166 shares during the last quarter. Nantahala Capital Management LLC boosted its stake in Soleno Therapeutics by 20.1% in the fourth quarter. Nantahala Capital Management LLC now owns 3,928,966 shares of the company's stock worth $176,607,000 after purchasing an additional 658,518 shares in the last quarter. Avoro Capital Advisors LLC grew its holdings in shares of Soleno Therapeutics by 15.8% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,525,000 shares of the company's stock worth $113,499,000 after purchasing an additional 344,000 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Soleno Therapeutics by 19.2% in the fourth quarter. Vanguard Group Inc. now owns 1,884,533 shares of the company's stock valued at $84,710,000 after buying an additional 303,806 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Soleno Therapeutics by 24.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,630,718 shares of the company's stock valued at $73,301,000 after buying an additional 321,223 shares during the last quarter. Institutional investors own 97.42% of the company's stock.

Insider Activity at Soleno Therapeutics

In other news, CEO Bhatnagar Anish sold 699,095 shares of the business's stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $67.62, for a total value of $47,272,803.90. Following the sale, the chief executive officer now owns 577,076 shares in the company, valued at approximately $39,021,879.12. The trade was a 54.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Patricia C. Hirano sold 128,653 shares of the company's stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $68.32, for a total transaction of $8,789,572.96. Following the completion of the sale, the insider now directly owns 55,789 shares in the company, valued at approximately $3,811,504.48. The trade was a 69.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 942,672 shares of company stock valued at $64,058,781 in the last 90 days. 12.30% of the stock is owned by corporate insiders.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.